Literature DB >> 1695256

Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.

K L van Wyke Coelingh1, C C Winter, E L Tierney, S L Hall, W T London, H W Kim, R M Chanock, B R Murphy.   

Abstract

An unusual feature of human parainfluenza virus type 3 (PIV3) is ita ability to cause reinfection with high efficiency. The antibody responses of 45 humans and 9 rhesus monkeys to primary infection or subsequent reinfection with PIV3 were examined to identify deficiencies in host immunologic responses that might contribute to the ability of the virus to cause reinfection with high frequency. Antibody responses in serum were tested by using neutralization and hemagglutination inhibition (HI) assays and a monoclonal antibody blocking immunoassay able to detect antibodies to epitopes within six antigenic sites on the PIV3 hemagglutinin-neuraminidase (HN) glycoprotein and eight antigenic sites on the fusion (F) protein. Primary infection of seronegative infants or children with PIV3 stimulated strong and rather uniform HI and neutralizing antibody responses. More than 90% of the individuals developed antibodies to four of the six HN antigenic sites (including three of the four neutralization sites), but the responses to F antigenic sites were of lesser magnitude and varied considerably from person to person. Young infants who possessed maternally derived antibodies in their sera developed lower levels and less frequent HI, neutralizing, and antigenic site-specific responses to the HN and F glycoproteins than did seronegative infants and children. In contrast, children reinfected with PIV3 developed even higher HI and neutralizing antibody responses than those observed during primary infection. Reinfection broadened the HN and F antigenic site-specific responses, but the latter remained relatively restricted. Adults possessed lower levels of HI, neutralizing, and antigenic site-specific antibodies in their sera than did children who had been reinfected, suggesting that these antibodies decay with time. Rhesus monkeys developed more vigorous primary and secondary antibody responses than did humans, but even in these highly responsive animals, response to the F glycoprotein was relatively restricted following primary infection. Bovine PIV3 induced a broader response to human PIV3 in monkeys than was anticipated on the basis of their known relatedness as defined by using monoclonal antibodies to human PIV3. These observations suggest that the restricted antibody responses to multiple antigenic sites on the F glycoprotein in young seronegative infants and children and the decreased responses to both the F and HN glycoproteins in young infants and children with maternally derived antibodies may play a role in the susceptibility of human infants and young children to reinfection with PIV3.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695256      PMCID: PMC249679     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  MYXOVIRUSES: PARAINFLUENZA.

Authors:  R M CHANOCK; R H PARROTT; K M JOHNSON; A Z KAPIKIAN; J A BELL
Journal:  Am Rev Respir Dis       Date:  1963-09

2.  Newly recognized myxoviruses from children with respiratory disease.

Authors:  R M CHANOCK; R H PARROTT; K COOK; B E ANDREWS; J A BELL; T REICHELDERFER; A Z KAPIKIAN; F M MASTROTA; R J HUEBNER
Journal:  N Engl J Med       Date:  1958-01-30       Impact factor: 91.245

3.  Role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response.

Authors:  R Ray; B J Glaze; R W Compans
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirus.

Authors:  K L van Wyke Coelingh; B R Murphy; P L Collins; A M Lebacq-Verheyden; J F Battey
Journal:  Virology       Date:  1987-10       Impact factor: 3.616

5.  Intranasal immunization of hamsters with envelope glycoproteins of human parainfluenza virus type 3.

Authors:  R Ray; B J Glaze; Z Moldoveanu; R W Compans
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

6.  Immunological studies of the functions of paramyxovirus glycoproteins.

Authors:  D C Merz; A Scheid; P W Choppin
Journal:  Virology       Date:  1981-02       Impact factor: 3.616

7.  Protection of weanling hamsters from experimental infection with wild-type parainfluenza virus type 3 (para 3) by cold-adapted mutants of para 3.

Authors:  F K Crookshanks-Newman; R B Belshe
Journal:  J Med Virol       Date:  1986-02       Impact factor: 2.327

8.  Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera.

Authors:  M L Wang; J J Skehel; D C Wiley
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

9.  Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

Authors:  V A Fulginiti; J J Eller; O F Sieber; J W Joyner; M Minamitani; G Meiklejohn
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

10.  Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge.

Authors:  K L van Wyke Coelingh; C C Winter; E L Tierney; W T London; B R Murphy
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

View more
  15 in total

1.  T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation.

Authors:  S R Chintalacharuvu; N U Nagy; N Sigmund; J G Nedrud; M E Amm; S N Emancipator
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  Comparison of different approaches to measuring influenza A virus-specific hemagglutination inhibition antibodies in the presence of serum inhibitors.

Authors:  E K Subbarao; Y Kawaoka; K Ryan-Poirier; M L Clements; B R Murphy
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

3.  Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.

Authors:  Anne Schaap-Nutt; Caraline Higgins; Emerito Amaro-Carambot; Sheila M Nolan; Christopher D'Angelo; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

4.  Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites.

Authors:  J A Simpson; J C Chow; J Baker; N Avdalovic; S Yuan; D Au; M S Co; M Vasquez; W J Britt; K L Coelingh
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

5.  The aberrant gene-end transcription signal of the matrix M gene of human parainfluenza virus type 3 downregulates fusion F protein expression and the F-specific antibody response in vivo.

Authors:  Matthias Lingemann; Sonja Surman; Emérito Amaro-Carambot; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

6.  Evidence of respiratory syncytial virus and parainfluenza-3 virus in Mexican sheep.

Authors:  M J Contreras-Luna; L A Ramírez-Martínez; R E Sarmiento Silva; C Cruz Lazo; A Pérez Torres; J I Sánchez-Betancourt
Journal:  Virusdisease       Date:  2017-02-27

7.  Antigenic determinants of measles virus hemagglutinin associated with neurovirulence.

Authors:  U G Liebert; S G Flanagan; S Löffler; K Baczko; V ter Meulen; B K Rima
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Suppression of lymphocyte proliferation by parainfluenza virus type 3-infected bovine alveolar macrophages.

Authors:  R J Basaraba; P R Brown; W W Laegreid; R M Silflow; J F Evermann; R W Leid
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

Review 9.  Biology of parainfluenza viruses.

Authors:  R Vainionpää; T Hyypiä
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

Review 10.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.